Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant

DISEASE CHARACTERISTICS: * Has undergone allogeneic stem cell transplantation (ASCT) for hematologic malignancy at least 30 days ago * No failure to engraft following transplant * No active acute or chronic graft-versus-host disease (GVHD) * Minimal GVHD allowed * Persistent or relapsed disease after ASCT, including 1 of the following: * Chronic myelogenous leukemia (CML), meeting any of the following criteria: * Molecular relapse (may be treated with imatinib mesylate after transplant), as defined by any of the following: * ASCT was non-T-cell depleted, a negative bcr/abl was documented by PCR post-transplant, and bcr/abl is now detectable by 2 consecutive PCR determinations \> 30 days apart * ASCT was non-T-cell depleted and bcr/abl is detectable by PCR at any time after day 180 post-transplant * Cytogenetic relapse after 3-6 months of imatinib mesylate * Relapsed chronic phase, accelerated phase, or blastic phase CML after 3-6 months of imatinib mesylate * Must currently be in chronic phase or accelerated phase CML only * Patients with blastic phase CML must attain a second chronic phase * Acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndromes, meeting any of the following criteria: * Molecular relapse, as evidenced by \< 5% blasts in the bone marrow and the patient's leukemia-specific molecular abnormality detectable by PCR * Cytogenetic relapse, as evidenced by \< 5% blasts in the…